Side-by-side · Research reference
PancragenvsProstamax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BAnimal-MechanisticHUMAN-REVIEWED11/38 cited
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
01Mechanism of Action
Parameter
Pancragen
Prostamax
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Feedback intact?
Yes — preserves physiological glucose-insulin response
—
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Prostamax
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
Human clinical dose
—
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
Age groups studied
—
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
Duration
—
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
04Side Effects & Safety
Parameter
Pancragen
Prostamax
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
Absent — no published Phase 1/2/3 trials
Published adverse events
—
None reported in available literature
Genotoxicity signals
—
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
Metal ion interactions
—
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
Absolute Contraindications
Pancragen
—Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
05Administration Protocol
Parameter
Pancragen
Prostamax
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
5. Note
—
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.